{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/wyhof78wiza",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1038/ncomms14207",
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1002/dad2.12391",
    "https://doi.org/10.18632/aging.205322",
    "https://doi.org/10.3390/ph17030270",
    "https://doi.org/10.1007/s00401-023-02574-0",
    "https://doi.org/10.1186/s13195-022-01128-y"
  ],
  "dcterms:references": [
    "# Mechanistic Hypothesis Linking DOPAL's Anti-Aβ Oligomerization Effects with Preserved Noradrenergic Function in Early Alzheimer's Disease\n\n## 1. Background\nDOPAL (3,4-dihydroxyphenylacetaldehyde), a reactive metabolite produced during dopamine oxidation by monoamine oxidase (MAO), has been shown to decrease Aβ oligomerization in human neuroblastoma cells, thereby reducing Aβ-mediated cytotoxicity. In early Alzheimer's disease, dopaminergic neurons in the ventral tegmental area (VTA) undergo selective degeneration, leading to reduced dopamine outflow in the hippocampus and impaired memory function (as shown in Abstract 1). Interestingly, noradrenergic projections from the locus coeruleus (LC) remain intact during this early stage, as evidenced by unchanged noradrenaline outflow in the hippocampus of 6-month-old Tg2576 mice compared to wild-type controls (Abstract 1). L-DOPA administration reduces Aβ pathology in 5xFAD mice by upregulating Aβ-degrading enzymes and attenuating neuroinflammation (Abstract 2).\n\n## 2. Knowledge Gap\nWhile DOPAL's anti-oligomerization effects and preserved noradrenergic function occur simultaneously in early AD, the potential mechanistic interaction between these phenomena remains unexplored. Specifically, it is unknown whether preserved noradrenergic signaling influences DOPAL production, utilization, or effectiveness in mitigating Aβ oligomerization, particularly in the context of declining dopaminergic function.\n\n## 3. Central Hypothesis\nPreserved noradrenergic signaling in early Alzheimer's disease enhances DOPAL production from residual dopaminergic terminals through adrenergic receptor-mediated regulation of MAO activity, creating a compensatory mechanism that delays Aβ oligomerization and promotes glymphatic clearance of soluble Aβ.\n\n## 4. Proposed Mechanism\n1. Noradrenaline released from preserved LC projections activates β-adrenergic receptors on the remaining dopaminergic terminals and surrounding astrocytes in the hippocampus, increasing intracellular cAMP levels and protein kinase A (PKA) activation.\n\n2. PKA-mediated phosphorylation enhances MAO-B activity in dopaminergic terminals, accelerating the conversion of residual dopamine to DOPAL in hippocampal regions receiving both dopaminergic and noradrenergic inputs.\n\n3. Simultaneously, noradrenergic signaling in astrocytes enhances glutathione production, preventing DOPAL auto-oxidation and directing it toward interaction with extracellular Aβ monomers.\n\n4. DOPAL binds to specific hydrophobic regions of Aβ monomers, inducing conformational changes that inhibit β-sheet formation necessary for oligomerization and increasing Aβ's susceptibility to degradation by NEP and ADAM17 (enzymes upregulated by L-DOPA, as shown in Abstract 2).\n\n5. Additionally, noradrenaline-stimulated astrocytes enhance glymphatic clearance of DOPAL-modified Aβ monomers (connecting to findings in the glymphatic clearance abstract), establishing a coordinated neuroprotective pathway that compensates for dopaminergic neuron loss in early AD.\n\n## 5. Testable Predictions\n1. Pharmacological blockade of β-adrenergic receptors in young Tg2576 mice should decrease hippocampal DOPAL levels, increase Aβ oligomerization, and accelerate cognitive decline compared to untreated controls.\n\n2. Selective LC lesioning (using DSP-4) in pre-symptomatic AD mouse models should reduce the ratio of DOPAL to dopamine in the hippocampus and increase Aβ oligomer formation, effects that could be rescued by direct application of synthetic DOPAL.\n\n3. The hippocampal concentration of DOPAL should positively correlate with noradrenaline levels across brain regions in human post-mortem samples from early-stage AD patients, and both should inversely correlate with oligomeric Aβ levels in the same regions.\n\n## 6. Potential Experimental Approaches\n1. Develop a microdialysis approach to simultaneously measure in vivo DOPAL, noradrenaline, and Aβ oligomer levels in the hippocampus of AD mouse models before and after pharmacological manipulation of adrenergic signaling or MAO activity. This could be combined with behavioral testing to correlate neurochemical changes with cognitive function.\n\n2. Create an ex vivo brain slice preparation from AD mouse models to visualize real-time interactions between noradrenergic and dopaminergic terminals using fluorescent sensors for noradrenaline, dopamine, DOPAL, and Aβ oligomerization. This system would allow for controlled manipulation of noradrenergic signaling while monitoring subsequent effects on DOPAL production and Aβ aggregation.\n\nThis hypothesis provides a novel mechanistic framework connecting preserved noradrenergic function with DOPAL-mediated protection against Aβ toxicity in early Alzheimer's disease. By identifying this potential compensatory pathway, we may better understand why noradrenergic systems are preserved in early disease stages and how their eventual deterioration might accelerate disease progression, potentially opening new therapeutic avenues targeting this noradrenaline-DOPAL-Aβ axis."
  ],
  "dcterms:subject": [
    "amyloid beta",
    "neurodegenerative diseases"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "Noradrenaline outflow in the hippocampus did not differ between wild-type and Tg2576 mice at 6 months of age, suggesting preserved noradrenergic projections from the locus coeruleus."
  ],
  "dcterms:abstract": [
    "The study examines dopaminergic neuron loss in Alzheimers disease focusing on the ventral tegmental area VTA in Tg2576 mice The research demonstrates selective loss of dopaminergic neurons specifically in the VTA during pre plaque stages contrasting with Parkinsons disease where neurons are lost in the substantia nigra pars compacta but preserved in VTA Apoptotic cell death contributes to VTA dopaminergic neuron degeneration affecting dopamine release in the hippocampus and impacting synaptic plasticity particularly in the hippocampal CA1 region Reduced dopamine outflow in Tg2576 mice leads to memory deficits and impaired reward processing while noradrenaline outflow remains unchanged indicating preserved noradrenergic projections from the locus coeruleus The study investigated several treatments Levodopa L DOPA administration successfully rescued multiple deficits including CA1 synaptic plasticity dendritic spine density hippocampal post synaptic density composition memory function and food reward processing L DOPA was administered at 10 mg kg along with benserazide at 12 mg kg Similarly selegiline a monoamine oxidase B inhibitor improved dopamine outflow in the hippocampus restored synaptic plasticity dendritic spine density memory performance and reward processing The treatment also restored D1 receptors and GluA1 expression in hippocampal PSD fractions These findings establish a clear link between dopamine signaling memory formation and reward processing in Alzheimers disease with dopaminergic dysfunction occurring at early stages The research suggests potential therapeutic approaches through dopamine system modulation using established drugs like L DOPA and selegiline",
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings.",
    "Glymphatic clearance dysfunction may play an important role in a variety of neurodegenerative diseases and the progression of ageing. However, in vivo imaging of the glymphatic system is challenging. In this study, we describe an MRI method based on chemical exchange saturation transfer (CEST) of the Angiopep-2 probe to visualize the clearance function of the glymphatic system.",
    "The bottleneck in drug discovery for central nervous system diseases is the absence of effective systemic drug delivery technology for delivering therapeutic drugs into the brain. Despite advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging. Here we describe the development of a novel brain-targeted drug delivery system that involves genetically engineered exosomes capable of high expression gene delivery in mice.",
    "Tau neurofibrillary tangles are a hallmark of Alzheimer’s disease neuropathological change. However, it remains largely unclear how distinctive Alzheimer’s disease tau seeds (i.e. 3R/4R) correlate with histological indicators of tau accumulation. Here, we use tau real-time quaking-induced conversion (RT-QuIC) assays to selectively quantitate 3R/4R tau seeds in the frontal lobe which accumulates histologically identifiable tau pathology at late disease stages of AD neuropathologic change.",
    "Granulovacuolar degeneration bodies (GVBs) are intracellular vesicular structures that commonly accompany pathological tau accumulations in neurons of patients with tauopathies. In this study, we show that GVBs are independently induced by tau and α-synuclein pathology, providing insights into their formation and implications in neurodegenerative diseases."
  ]
}